The clinical significance of an isofunctioning thyroid nodule

Nasim Hedayati, Christopher R. McHenry

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The management of an "isofunctioning" thyroid nodule - defined by radioiodine uptake equivalent to normal thyroid tissue - is often a dilemma. Our goal was to determine the percentage of thyroid nodules that were isofunctioning and the frequency with which carcinoma occurred in an isofunctioning nodule. Patients referred for evaluation of a thyroid nodule from 1990 to 2002 were reviewed and those with an iodine-123 thyroid scintiscan were identified. Nodule size, serum thyrotropin, fine-needle aspiration biopsy, pathology, and follow-up were determined for patients with an isofunctioning, hypofunctioning, or hyperfunctioning thyroid nodule. Of the 562 patients with a thyroid nodule 273 (49%) had a thyroid scan. Nodules were hypofunctioning in 232 (85%), isofunctioning in 29 (11%), and hyperfunctioning in 12 (4%) patients. Mean nodule size and serum thyrotropin level were respectively 2.49 ± 0.23 cm and 1.73 ± 0.26 μIU/mL for isofunctioning, 2.47 ± 0.31 cm and 0.83 ± 0.21 μIU/mL for hyperfunctioning, and 3.94 ± 0.13 cm and 1.86 ± 0.28 μIU/mL for hypofunctioning nodules. Seventeen patients with an isofunctioning nodule underwent thyroidectomy and 12 patients were followed for a mean 27 months without an increase in nodule size. No patient with a hyperfunctioning nodule, six patients (21%) with an isofunctioning nodule, and 44 patients (19%) with a hypofunctioning nodule had a carcinoma. We conclude that the risk of malignancy in an isofunctioning nodule is similar to that of a hypofunctioning nodule and therefore the management should be based on routine fine-needle aspiration biopsy.

Original languageEnglish (US)
Pages (from-to)311-315
Number of pages5
JournalAmerican Surgeon
Volume69
Issue number4
StatePublished - 2003
Externally publishedYes

Fingerprint

Thyroid Nodule
Thyroid Gland
Thyrotropin
Fine Needle Biopsy
Carcinoma
Thyroidectomy
Serum
Iodine
Pathology

ASJC Scopus subject areas

  • Surgery

Cite this

The clinical significance of an isofunctioning thyroid nodule. / Hedayati, Nasim; McHenry, Christopher R.

In: American Surgeon, Vol. 69, No. 4, 2003, p. 311-315.

Research output: Contribution to journalArticle

Hedayati, Nasim ; McHenry, Christopher R. / The clinical significance of an isofunctioning thyroid nodule. In: American Surgeon. 2003 ; Vol. 69, No. 4. pp. 311-315.
@article{17a62c450992488a8c74badc032d913d,
title = "The clinical significance of an isofunctioning thyroid nodule",
abstract = "The management of an {"}isofunctioning{"} thyroid nodule - defined by radioiodine uptake equivalent to normal thyroid tissue - is often a dilemma. Our goal was to determine the percentage of thyroid nodules that were isofunctioning and the frequency with which carcinoma occurred in an isofunctioning nodule. Patients referred for evaluation of a thyroid nodule from 1990 to 2002 were reviewed and those with an iodine-123 thyroid scintiscan were identified. Nodule size, serum thyrotropin, fine-needle aspiration biopsy, pathology, and follow-up were determined for patients with an isofunctioning, hypofunctioning, or hyperfunctioning thyroid nodule. Of the 562 patients with a thyroid nodule 273 (49{\%}) had a thyroid scan. Nodules were hypofunctioning in 232 (85{\%}), isofunctioning in 29 (11{\%}), and hyperfunctioning in 12 (4{\%}) patients. Mean nodule size and serum thyrotropin level were respectively 2.49 ± 0.23 cm and 1.73 ± 0.26 μIU/mL for isofunctioning, 2.47 ± 0.31 cm and 0.83 ± 0.21 μIU/mL for hyperfunctioning, and 3.94 ± 0.13 cm and 1.86 ± 0.28 μIU/mL for hypofunctioning nodules. Seventeen patients with an isofunctioning nodule underwent thyroidectomy and 12 patients were followed for a mean 27 months without an increase in nodule size. No patient with a hyperfunctioning nodule, six patients (21{\%}) with an isofunctioning nodule, and 44 patients (19{\%}) with a hypofunctioning nodule had a carcinoma. We conclude that the risk of malignancy in an isofunctioning nodule is similar to that of a hypofunctioning nodule and therefore the management should be based on routine fine-needle aspiration biopsy.",
author = "Nasim Hedayati and McHenry, {Christopher R.}",
year = "2003",
language = "English (US)",
volume = "69",
pages = "311--315",
journal = "American Surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "4",

}

TY - JOUR

T1 - The clinical significance of an isofunctioning thyroid nodule

AU - Hedayati, Nasim

AU - McHenry, Christopher R.

PY - 2003

Y1 - 2003

N2 - The management of an "isofunctioning" thyroid nodule - defined by radioiodine uptake equivalent to normal thyroid tissue - is often a dilemma. Our goal was to determine the percentage of thyroid nodules that were isofunctioning and the frequency with which carcinoma occurred in an isofunctioning nodule. Patients referred for evaluation of a thyroid nodule from 1990 to 2002 were reviewed and those with an iodine-123 thyroid scintiscan were identified. Nodule size, serum thyrotropin, fine-needle aspiration biopsy, pathology, and follow-up were determined for patients with an isofunctioning, hypofunctioning, or hyperfunctioning thyroid nodule. Of the 562 patients with a thyroid nodule 273 (49%) had a thyroid scan. Nodules were hypofunctioning in 232 (85%), isofunctioning in 29 (11%), and hyperfunctioning in 12 (4%) patients. Mean nodule size and serum thyrotropin level were respectively 2.49 ± 0.23 cm and 1.73 ± 0.26 μIU/mL for isofunctioning, 2.47 ± 0.31 cm and 0.83 ± 0.21 μIU/mL for hyperfunctioning, and 3.94 ± 0.13 cm and 1.86 ± 0.28 μIU/mL for hypofunctioning nodules. Seventeen patients with an isofunctioning nodule underwent thyroidectomy and 12 patients were followed for a mean 27 months without an increase in nodule size. No patient with a hyperfunctioning nodule, six patients (21%) with an isofunctioning nodule, and 44 patients (19%) with a hypofunctioning nodule had a carcinoma. We conclude that the risk of malignancy in an isofunctioning nodule is similar to that of a hypofunctioning nodule and therefore the management should be based on routine fine-needle aspiration biopsy.

AB - The management of an "isofunctioning" thyroid nodule - defined by radioiodine uptake equivalent to normal thyroid tissue - is often a dilemma. Our goal was to determine the percentage of thyroid nodules that were isofunctioning and the frequency with which carcinoma occurred in an isofunctioning nodule. Patients referred for evaluation of a thyroid nodule from 1990 to 2002 were reviewed and those with an iodine-123 thyroid scintiscan were identified. Nodule size, serum thyrotropin, fine-needle aspiration biopsy, pathology, and follow-up were determined for patients with an isofunctioning, hypofunctioning, or hyperfunctioning thyroid nodule. Of the 562 patients with a thyroid nodule 273 (49%) had a thyroid scan. Nodules were hypofunctioning in 232 (85%), isofunctioning in 29 (11%), and hyperfunctioning in 12 (4%) patients. Mean nodule size and serum thyrotropin level were respectively 2.49 ± 0.23 cm and 1.73 ± 0.26 μIU/mL for isofunctioning, 2.47 ± 0.31 cm and 0.83 ± 0.21 μIU/mL for hyperfunctioning, and 3.94 ± 0.13 cm and 1.86 ± 0.28 μIU/mL for hypofunctioning nodules. Seventeen patients with an isofunctioning nodule underwent thyroidectomy and 12 patients were followed for a mean 27 months without an increase in nodule size. No patient with a hyperfunctioning nodule, six patients (21%) with an isofunctioning nodule, and 44 patients (19%) with a hypofunctioning nodule had a carcinoma. We conclude that the risk of malignancy in an isofunctioning nodule is similar to that of a hypofunctioning nodule and therefore the management should be based on routine fine-needle aspiration biopsy.

UR - http://www.scopus.com/inward/record.url?scp=0038653528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038653528&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 311

EP - 315

JO - American Surgeon

JF - American Surgeon

SN - 0003-1348

IS - 4

ER -